Medicalisation, limits to medicine, or never enough money to go around?
- PMID: 11950720
- PMCID: PMC1122818
- DOI: 10.1136/bmj.324.7342.864
Medicalisation, limits to medicine, or never enough money to go around?
Comment on
-
Economic benefit analysis of primary prevention with pravastatin. Assumptions are methodologically flawed.BMJ. 1998 Apr 18;316(7139):1241-2. BMJ. 1998. PMID: 9583930 No abstract available.
References
-
- Illich I. Limits to medicine: medical nemesis, the expropriation of health. New edition. London: Boyars; 1976.
-
- Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA. Recent patterns of medication use in the ambulatory adult population in the United States: the Sloan survey. JAMA. 2002;287:337–344. - PubMed
-
- Pecoul B, Chirac P, Trouiller P, Pinel J. Access to essential drugs in poor countries: a lost battle? JAMA. 1999;281:361–367. - PubMed
-
- Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S) Lancet. 1994;344:1383–1389. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources